Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Sacituzumab tirumotecan in PD-L1 negative Triple Negative Breast Cancer: NCT06279364 Clinical Landscape Report 2026
16 October 2026
NCT06279364 clinical landscape for PD-L1 negative Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Toripalimab in Metastatic Renal Cell Carcinoma: NCT06279403 Clinical Landscape Report 2026
16 October 2026
NCT06279403 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SC-262 in Large B-cell lymphoma: NCT06285422 Clinical Landscape Report 2026
16 October 2026
NCT06285422 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PF-07820435 in Ovarian Cancer: NCT06285097 Clinical Landscape Report 2026
16 October 2026
NCT06285097 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
DCC-3084 in Pancreatic Ductal Adenocarcinoma: NCT06287463 Clinical Landscape Report 2026
16 October 2026
NCT06287463 clinical landscape for Pancreatic Ductal Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Evolocumab in Metastatic Renal Cell Carcinoma: NCT06284564 Clinical Landscape Report 2026
16 October 2026
NCT06284564 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tuparstobart in Follicular Lymphoma: NCT06290622 Clinical Landscape Report 2026
16 October 2026
NCT06290622 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Epcoritamab in High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: NCT06287398 Clinical Landscape Report 2026
16 October 2026
NCT06287398 clinical landscape for High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: endpoints, sponsor, phase, geography, readouts, a…
9 min read
Trastuzumab Brengitecan in HER2 Positive Solid Tumors: NCT06293898 Clinical Landscape Report 2026
16 October 2026
NCT06293898 clinical landscape for HER2 Positive Solid Tumors: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ifosamide in Synovial Sarcoma: CTRI/2024/03/063743 Clinical Landscape Report 2026
16 October 2026
CTRI/2024/03/063743 clinical landscape for Synovial Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Malignant melanoma stage IV: NCT06295159 Clinical Landscape Report 2026
16 October 2026
NCT06295159 clinical landscape for Malignant melanoma stage IV: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NM32-2668 in Endometrial Carcinoma: NCT06299163 Clinical Landscape Report 2026
16 October 2026
NCT06299163 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.